tetano
Editor, Senior Moderator
mBio
. 2023 Dec 21:e0287823.
doi: 10.1128/mbio.02878-23. Online ahead of print. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment
Pengfei Li[SUP] 1 [/SUP], Yunjeong Kim[SUP] 2 [/SUP], Chamandi S Dampalla[SUP] 3 [/SUP], Harry Nhat Nguyen[SUP] 3 [/SUP], David K Meyerholz[SUP] 4 [/SUP], David K Johnson[SUP] 5 [/SUP], Scott Lovell[SUP] 6 [/SUP], William C Groutas[SUP] 3 [/SUP], Stanley Perlman[SUP] 1 [/SUP], Kyeong-Ok Chang[SUP] 2 [/SUP]
Affiliations
Human coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) continue to have a significant impact on public health. A limited or lacking therapeutic arsenal for SARS-CoV-2 and MERS-CoV infections calls for an expanded and diversified portfolio of antivirals against these coronavirus infections. We have previously reported a series of small-molecule 3C-like protease (3CLpro) inhibitors against human coronaviruses. In this report, we demonstrated the in vivo efficacy of 3CLpro inhibitors for their broad-spectrum activity against both SARS-CoV-2 and MERS-CoV infections using the fatal animal models. The results suggest that these are promising candidates for further development as broad-spectrum direct-acting antivirals against highly virulent human coronaviruses.
Keywords: 3CLpro; MERS-CoV; SARS-CoV-2; animal models; protease inhibitors.
. 2023 Dec 21:e0287823.
doi: 10.1128/mbio.02878-23. Online ahead of print. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment
Pengfei Li[SUP] 1 [/SUP], Yunjeong Kim[SUP] 2 [/SUP], Chamandi S Dampalla[SUP] 3 [/SUP], Harry Nhat Nguyen[SUP] 3 [/SUP], David K Meyerholz[SUP] 4 [/SUP], David K Johnson[SUP] 5 [/SUP], Scott Lovell[SUP] 6 [/SUP], William C Groutas[SUP] 3 [/SUP], Stanley Perlman[SUP] 1 [/SUP], Kyeong-Ok Chang[SUP] 2 [/SUP]
Affiliations
- PMID: 38126789
- DOI: 10.1128/mbio.02878-23
Human coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) continue to have a significant impact on public health. A limited or lacking therapeutic arsenal for SARS-CoV-2 and MERS-CoV infections calls for an expanded and diversified portfolio of antivirals against these coronavirus infections. We have previously reported a series of small-molecule 3C-like protease (3CLpro) inhibitors against human coronaviruses. In this report, we demonstrated the in vivo efficacy of 3CLpro inhibitors for their broad-spectrum activity against both SARS-CoV-2 and MERS-CoV infections using the fatal animal models. The results suggest that these are promising candidates for further development as broad-spectrum direct-acting antivirals against highly virulent human coronaviruses.
Keywords: 3CLpro; MERS-CoV; SARS-CoV-2; animal models; protease inhibitors.